News

Phase II osteoarthritis clinical trial underway in Denmark



The APPA Phase II human trial is being conducted by AKL Research & Development's (AKLRD) partner Nordic Bioscience Clinical Development (NBCD), following the successful completion of Phase I. The study is a placebo-controlled, double-blind, randomized trial evaluating the efficacy and safety of oral APPA in 150 patients with osteoarthritis of the knee and is being conducted by NBCD at three clinical centres in Denmark, with results expecte...
Read More

Partnership with world-leading animal health company



AKL Research and Development has partnered with a world-leading animal health company to test APPA in dogs AKLRD has signed an agreement with one of the world’s top five animal health companies to fund the development of its next-stage clinical trial in canine OA. Osteoarthritis is the most common form of arthritis in dogs, affecting approximately a quarter of the population. Under the terms of the agreement, AKLRD’s partner will fund a...
Read More

Abstract published at EULAR 2020



An abstract on a series of uncontrolled patient cases evaluating the efficacy and safety of APPA in patients with osteoarthritis has been published at EULAR 2020 Treatment with APPA was reported as effective by 82.6% of patients, all of whom had failed to have an adequate response with standard prescribed medications. Full abstract is available here....
Read More

New research published on APPA’s mode of action



APPA modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNFα expression and signalling A greater understanding of neutrophil biology has led to an appreciation that these cells play a significant role in many systemic inflammatory conditions but targeting neutrophils therapeutically has proven challenging, as host defences must not be compromised. Neutrophils contribute to infl...
Read More

Positive result in APPA Phase I clinical trial



AKLRD has successfully completed a Phase I APPA in Osteoarthritis (OA) trial. The Principal Investigator of this study summarized in the results that the primary endpoint had been met as “APPA was demonstrated to be safe and well-tolerated by all subjects in the trial”. The full study report will be available shortly. The National Institute for Health Research (NIHR) support approved Phase 1 study, sponsored by University of Liverpool, was...
Read More

Important new evidence on the mode of action of APPA



Previous work has shown that the anti-inflammatory effects seen with APPA results from upregulation of Nrf-2 and reduction of NF-kB activity (see news item Summary of Effects of APPA on Neutrophils). Harmonisation of the molecular cross-talk between these intracellular messengers is known to reduce the levels of COX-1 and COX-2, enzymes that are inhibited by NSAIDs and thought to be involved in NSAIDs' side effect profiles including heart fail...
Read More

Former investment banker appointed CFO of AKL



AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Michael Martin as its Chief Financial Officer. With more than 40 years’ global corporate finance experience advising companies in Mergers & Acquisitions, Initial Public Offerings and private equity, Mr Martin brings a wealth of deal experience to the AKL management team.  His appointment c...
Read More

AKLRD and Nordic Bioscience announce collaboration



AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.  The partnership will assess the effectiveness of APPA both in relieving OA pain and in ...
Read More